Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-81.79%
operating margin TTM
-73.77%
revenue TTM
527.24 Million
revenue per share TTM
5.35$
valuation ratios | |
|---|---|
| pe ratio | -2.51 |
| peg ratio | 0.40 |
| price to book ratio | -5.14 |
| price to sales ratio | 2.02 |
| enterprise value multiple | -0.78 |
| price fair value | -5.14 |
profitability ratios | |
|---|---|
| gross profit margin | 83.12% |
| operating profit margin | -73.77% |
| pretax profit margin | -81.25% |
| net profit margin | -81.79% |
| return on assets | -46.39% |
| return on equity | 392.35% |
| return on capital employed | -57.93% |
liquidity ratios | |
|---|---|
| current ratio | 1.73 |
| quick ratio | 1.56 |
| cash ratio | 0.36 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 177.99 |
| operating cycle | 279.81 |
| days of payables outstanding | 117.65 |
| cash conversion cycle | 162.16 |
| receivables turnover | 3.58 |
| payables turnover | 3.10 |
| inventory turnover | 2.05 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.95 |
| debt equity ratio | -4.13 |
| long term debt to capitalization | 1.35 |
| total debt to capitalization | 1.32 |
| interest coverage | -6.95 |
| cash flow to debt ratio | -0.40 |
cash flow ratios | |
|---|---|
| free cash flow per share | -4.80 |
| cash per share | 2.87 |
| operating cash flow per share | -4.76 |
| free cash flow operating cash flow ratio | 1.01 |
| cash flow coverage ratios | -0.40 |
| short term coverage ratios | -6.38 |
| capital expenditure coverage ratio | -115.10 |
Frequently Asked Questions
When was the last time Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) reported earnings?
Ultragenyx Pharmaceutical Inc. (RARE) published its most recent earnings results on 05-08-2026.
What is Ultragenyx Pharmaceutical Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)'s trailing twelve months ROE is 392.35%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Ultragenyx Pharmaceutical Inc. (RARE) currently has a ROA of -46.39%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did RARE's net profit margin stand at?
RARE reported a profit margin of -81.79% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is RARE's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 1.73 in the most recent quarter. The quick ratio stood at 1.56, with a Debt/Eq ratio of -4.13.